Chemotherapy is one of the most common forms of cancers treatments. The medication aims at destroying cancer cells. Platinum-based chemotherapy drugs are used to treat various cancer types such as lung, breast,…
Tag: Lung Cancer Drugs
Targeted Therapy Better than Immunotherapy in Some Patients with NSCLC
Non-small cell lung cancer continues to remain one of the main reasons behind cancer related deaths all across the world. Continuous studies and research works are going on that could help in…
Quratusugene Ozeplasmid for Small Cell Lung Cancer Receives Orphan Drug Designation by FDA
Genprex, Inc. is a clinical-stage gene therapy company and has announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the drug, Reqorsa Immunogene Therapy (quratusugene…
Lung Cancer Drug, Osimertinib, Drastically Reduces Death Risk after Surgery
Lung cancer is among most common types of cancers in U.S. as well as around the world. According to the Centers for Disease Control and Prevention, it is responsible for nearly a…
FDA Approves Adjuvant Pembrolizumab for Non-Small Cell Lung Cancer Treatment
The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the…
U.S. FDA Approves Lung Cancer Drug, Adagrasib
The US Food and Drug Administration (FDA) has granted accelerated approval for Mirati Therapeutics’ Krazati (adagrasib) for treatment of mutated locally advanced or metastatic non-small cell lung cancer in adults. This accelerated…
FDA Grants Approval to Trastuzumab Deruxtecan for HER2 Lung Cancer
Lung cancer patients now have another treatment option. For those tumors carrying HER2 mutations, can now be treated with trastuzumab deruxtecan. This drug is already approved for use in HER2-positive breast cancer…
FDA Approves FoundationOne CDx in Non-Small Cell Lung Cancer
U.S. Food and Drug Administration (FDA) has approved the FoundationOne CDx as a companion diagnostic to guide treatment selection for patients with non-small cell lung cancer. This approval applies to the use…